Evidence map›Paper›PMID 37610476›Full record

ArticleArchives of toxicology2023

"Catch-up" therapy: combining antidotal treatment with dermal application of AHA following percutaneous VX poisoning in the domestic swine.

Eugenia Bloch-Shilderman, Uri Nili, Victoria Nahum, Boris Smolkin, Nissan Ashkenazi

Abstract read
PubMed Publisher
In one paragraph

Article in Archives of toxicology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. From Mechanisms to Materials: Oximate Reactivity and Emerging Strategies for Organophosphate Detoxification.Chemphyschem : a European journal of chemical physics and physical chemistry · 2026
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Eugenia Bloch-ShildermanDepartment of Pharmacology, IIBR-Israel Institute for Biological Research, P.O. Box 19, 7410001, Ness Ziona, Israel. eugenias@iibr.gov.il.ORCID http://orcid.org/0009-0009-8962-6686
Uri NiliDepartment of Pharmacology, IIBR-Israel Institute for Biological Research, P.O. Box 19, 7410001, Ness Ziona, Israel.
Victoria NahumDepartment of Organic Chemistry, IIBR-Israel Institute for Biological Research, P.O. Box 19, 7410001, Ness Ziona, Israel.
Boris SmolkinDepartment of Organic Chemistry, IIBR-Israel Institute for Biological Research, P.O. Box 19, 7410001, Ness Ziona, Israel.
Nissan AshkenaziDepartment of Organic Chemistry, IIBR-Israel Institute for Biological Research, P.O. Box 19, 7410001, Ness Ziona, Israel. nissan.ashkenazi@iibr.gov.il.ORCID http://orcid.org/0000-0003-0737-6994
Israel Institute for Biological Research · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Low-volatility organophosphorus chemical warfare agents (OP CWAs) are cholinesterase inhibitors which easily absorb into the skin, leading to the formation of a dermal depot from which they slowly enter the bloodstream. This leads to sustained cholinergic hyperstimulation, which if untreated may lead to death. However, current available countermeasures are not adequate to neutralize the agent residing in the dermal depot. Accordingly, we evaluated the efficacy of the potassium salt of acetohydroxamic acid (880 mg/ml in DMSO/H

Indexed as

Chemical Warfare AgentsOrganothiophosphorus CompoundsAnimalsAntidotesCholinesterase InhibitorsSwineAntidotesChemical Warfare AgentsCholinesterase InhibitorsOrganothiophosphorus CompoundsVX-agentAcetohydroxamic acid (AHA)AHAK“Catch-up” therapyDermal depotLow-volatility OP CWAsPercutaneous poisoning/exposureVX

Identifiers

PMID37610476
OpenAlexW4386083961

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.